Susan Melin to Dose-Response Relationship, Drug
This is a "connection" page, showing publications Susan Melin has written about Dose-Response Relationship, Drug.
Connection Strength
0.119
-
Miller AA, Case D, Harmon M, Savage P, Lesser G, Hurd D, Melin SA. Phase I study of lenalidomide in solid tumors. J Thorac Oncol. 2007 May; 2(5):445-9.
Score: 0.066
-
Lawrence JA, Akman SA, Melin SA, Case LD, Schwartz GG. Oral paricalcitol (19-nor-1,25-dihydroxyvitamin D2) in women receiving chemotherapy for metastatic breast cancer: a feasibility trial. . 2013 Jun; 14(6):476-80.
Score: 0.025
-
Ramanathan RK, Picus J, Raftopoulos H, Bernard S, Lockhart AC, Frenette G, Macdonald J, Melin S, Berg D, Brescia F, Hochster H, Cohn A. A phase II study of milataxel: a novel taxane analogue in previously treated patients with advanced colorectal cancer. Cancer Chemother Pharmacol. 2008 Mar; 61(3):453-8.
Score: 0.017
-
Blackstock AW, Melin SA, Butler JM, Patton S, Pineau B, Albertson D, Howerton R, Levine E. Irinotecan/gemcitabine followed by twice-weekly gemcitabine/radiation in locally advanced pancreatic cancer. Oncology (Williston Park). 2002 May; 16(5 Suppl 5):25-8.
Score: 0.012